Antibody Therapeutics Xchange Europe
Finding the best targets and binder combination for bi- or multispecific antibodies
- The use of standard therapeutic antibodies created with conventional lead generation processes have reached their limitations. New target combinations, exploiting rare epitopes or identifying novel bispecific combinations in different antibody formats are urgently needed to find novel applications in various disease settings.
- How do we best select new target (and epitope) combinations that are biologically meaningful and hold promise to tackle novel disease biology?
- How can we generate maximal binder and antibody format diversity to identify highly differentiated biologics?
- What are our experiences and learnings from the use of novel high-throughput technologies and combinatorial platforms to rapidly generate bispecific antibody combinations in differing formats that offer tailored solutions and novel mode-of-actions to address challenging biology
- Is this class of targets feasibly addressable or purely aspirational?
- What are the notable advances/inroads?
- Are there particular challenges and limitations to the ‘TCR mimic’ antibody approach?
How to select targets for immunotherapy combinations
- Immunotherapy targeting PD-1/PD-L1 or CTLA-4 has shown impressive results in various cancer indications; however, only a subset of patients respond to single agent therapy.
- Combination immunotherapy presents an opportunity for improving responses and outcomes for cancer patients.
- Currently, 1000s of combination trials are ongoing.
- The development of immunotherapy combinations faces a number of challenges, including selection and validation of targets
11:50am – 12:20pm
11:50am – 12:20pm
4:50pm – 4:55pm